In brief, CLIA by YHLO Biotech Co. was considered as the system with the best predictive power, where 58.55 and 57.89% of APS patients were positive for aCL or aβ2GPI for at least one antibodies (IgG or IgM or IgA). The gene discussed is CD79A; the disease is autoimmune polyendocrinopathy.